Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.
Haematology · Blood · 2026-11-12
RCTn = 49
Palmer et al. Sapablursen for erythrocytosis control in patients with polycythemia veraHaematology · Lancet Haematol · 2026-11-01
RCTn = 130
Hu et al. Decitabine plus busulfan-cyclophosphamide versus busulfan-cyclophosphamide myeloablative conditioning before allogeneic haematopoietic stem cell transplantation for reducing risk of relapse in adult KMT2A‑rearranged leukaemia in China: an open-label, multicentre, randomised phase 3 trialHaematology · Lancet · 2026-10-24
RCTn = 207
Andemariam et al. Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trialHaematology · JAMA · 2026-10-13
RCTn = 274
Morris et al. Arginine Therapy for Sickle Cell Disease Acute Pain Episodes: The STArT Randomized Clinical TrialHaematology · Lancet Haematol · 2026-10-01
RCTn = 295
He et al. Felzartamab plus lenalidomide-dexamethasone versus lenalidomide-dexamethasone for relapsed or refractory multiple myeloma: an open-label, parallel-controlled, randomised, phase 3 trialHaematology · Lancet Haematol · 2026-09-17
Open-label extensionn = 180
Kuter et al. Clinical activity and safety of rilzabrutinib in patients with previously treated immune thrombocytopenia (LUNA3): results from the open-label period of a phase 3 trialHaematology · Lancet Haematol · 2026-09-16
RCTn = 24
Markova et al. Topical ruxolitinib for chronic cutaneous graft-versus-host disease: a single-centre, randomised, double-blind, intra-patient-controlled phase 2 trialHaematology · Lancet · 2026-09-12
RCTn = 258
Cappellini et al. Efficacy and safety of mitapivat in adults with transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE-T): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trialHaematology · Lancet Haematol · 2026-09-01
RCTn = 73
Abramson et al. Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2-3 trial